



Department of Health and Human Services
MaineCare Services
Pharmacy Unit
11 State House Station
Augusta, Maine 04333-0011
Toll Free (866) 796-2463; Fax: (207) 287-8601
TTY Users: Dial 711 (Maine Relay)

To: MaineCare Providers
From: Roger Bondeson – Director of Operations
Date: March 9, 2017
Re: PDL Update for **3/10/2017**

The following medications have been recently added/changed to the MaineCare PDL as non-preferred and will require prior authorization.

Bromsite	Emverm	Invokamet XR	Inflectra	Jentaducto XR
Onzetra Xsail	Otovel	Qbrexelis	Relistor	Sustol

The following medication have been recently added to the MaineCare PDL as well as new PDL criteria.

Byvalson will be non-preferred with a DDI: Byvalson will be non-preferred and require a prior authorization if it is currently being used in combination with drugs known to be significant CYP2D6 inhibitors (e.g. quinidine, propafenone, fluoxetine, paroxetine).

Exondy 51 will be non-preferred and require a clinical prior authorization to verify diagnosis and use of stable dose of corticosteroid for at least 6 months.

Probuphine will be non-preferred and require both provider and patient to be registered as part of the Probuphine REMS program.

Brand Name Suboxone Tabs are being removed from the PDL as they are no longer available.

Zurampic will be non-preferred and should be used in combination with a xanthine oxidase inhibitor, including allopurinol or febuxostat.

Escitalopram will be preferred no longer requiring tablet splitting or age restrictions.

If you have any questions, please contact GHS at 1-888-420-9711.